Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer
Cellular Oncology · 2025-08 · 48 (4) · 1105-1119
DOI: 10.1007/s13402-025-01067-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 13.05.2025. Verfasst von Jiaqi Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen Uni…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cancer-Associated Fibroblasts, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Program, Sun Yat-sen University Clinical Research 5010 Program.
Abstract (Originalsprache)
Purpose
Immunotherapy has transformed the neoadjuvant treatment landscape for patients with resectable locally advanced non-small cell lung cancer (NSCLC). However, a population of patients cannot obtain major pathologic response (MPR) and thus benefit less from neoadjuvant immunotherapy, highlighting the need to uncover the underlying mechanisms driving resistance to immunotherapy.
Methods
Two published single-cell RNA sequencing (scRNA-seq) datasets were used to analyze the subsets of cancer-associated fibroblasts (CAFs) and T cells and functional alterations after neoadjuvant immunotherapy. The stromal signature predicting ICI response was identified and validated using our local cohort with stage III NSCLC receiving neoadjuvant immunotherapy and other 4 public ICI transcriptomic cohorts.
Results
Non-MPR tumors showed higher enrichment of CAFs and increased extracellular matrix deposition than MPR tumors, as suggested by bioinformatic analysis. Further, CAF-mediated immune suppression may involve reciprocal interactions with T cells in addition to a physical barrier mechanism. In contrast, MPR tumors demonstrated therapy-induced activation of memory CD8 + T cells into an effector phenotype. Additionally, neoadjuvant immunotherapy resulted in expansion of precursor exhausted T (Texp) cells, which were remodeled into an anti-tumor phenotype. Notably, we identified metabolic heterogeneity within distinct T cell clusters during immunotherapy. Methionine recycling emerged as a predictive factor for T-cell differentiation and a favorable pathological response. The stromal signature was associated with ICI response, and this association was validated in five independent ICI transcriptomic cohorts.
Conclusion
These discoveries underscore the distinct tumor microenvironments in MPR and non-MPR patients and may elucidate resistance mechanisms to immunotherapy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou City, Gu…
- Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
- Guangzhou BioScript Biotechnology Co., Ltd, Guangzhou, PR China.
- The Department of Breast Disease, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, PR China.
- Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou City, Gu…
Förderung
- National Natural Science Foundation of China
- Guangzhou Science and Technology Program
- Sun Yat-sen University Clinical Research 5010 Program
- Excellent Surgery Study Project of the Bethune Charitable Foundation
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhao, J., Liu, M., Zhu, C., Li, Z., Liu, Z., Abulizi, D., Liu, S., Wang, X., Yang, H., & Hou, X. (2025). Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer. Cellular Oncology, 48(4), 1105-1119. https://doi.org/10.1007/s13402-025-01067-4
Vancouver
Zhao J, Liu M, Zhu C, Li Z, Liu Z, Abulizi D, et al. Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer. Cellular Oncology. 2025;48(4):1105-1119. doi:10.1007/s13402-025-01067-4
BibTeX
@article{Zhao2025,
author = {Zhao, Jiaqi and Liu, Maolin and Zhu, Chongmei and Li, Zhuolin and Liu, Zuhui and Abulizi, Dilimulati and Liu, Siqing and Wang, Xin and Yang, Haoxian and Hou, Xue},
title = {Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer},
journal = {Cellular Oncology},
year = {2025},
volume = {48},
number = {4},
pages = {1105--1119},
doi = {10.1007/s13402-025-01067-4}
}
EUVIMED